4/12/2023

Penicillin G Benzathine

Products Affected - Description

- Bicillin L-A intramuscular suspension for injection, Pfizer, 1,200,000 units, 2 mL syringe, 10 count, NDC 60793-0701-10
- Bicillin L-A intramuscular suspension for injection, Pfizer, 2,400,000 units, 4 mL syringe, 10 count, NDC 60793-0702-10
- Bicillin L-A intramuscular suspension for injection, Pfizer, 600,000 units, 1 mL syringe, 10 count, NDC 60793-0700-10

Reason for the Shortage

- Pfizer has Bicillin-LA on shortage due to increased demand.
- Pfizer is the sole supplier of penicillin G benzathine injection.

Available Products

- There is insufficient supply for usual ordering

Estimated Resupply Dates

- Pfizer has Bicillin-LA 600,000 units/mL 1 mL, 2 mL, and 4 mL syringes available in limited supply. Pfizer is allocating at 100% of historical demand.

Implications for Patient Care

- CDC has a Technical Assistance Note regarding tracking and forecasting penicillin G benzathine injection due to the intermittent shortages of the product. This document is aimed to help public health entities ensure they have supply of penicillin G benzathine for patients with syphilis. This note can be found at: https://www.cdc.gov/std/funding/docs/STD-PCHD-TA-Notes-11c-Benzathine-Penicillin-G.pdf

Updated

Updated April 12, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 1, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.